- Home
- HVT vs RIGL Comparison
HVT vs RIGL Comparison
Compare HVT & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HVT
- RIGL
- Stock Information
- Founded
- HVT 1885
- RIGL 1996
- Country
- HVT United States
- RIGL United States
- Employees
- HVT N/A
- RIGL N/A
- Industry
- HVT Other Specialty Stores
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- HVT Consumer Discretionary
- RIGL Health Care
- Exchange
- HVT Nasdaq
- RIGL Nasdaq
- Market Cap
- HVT 329.5M
- RIGL 335.5M
- IPO Year
- HVT N/A
- RIGL 2000
- Fundamental
- Price
- HVT $22.74
- RIGL $37.96
- Analyst Decision
- HVT
- RIGL Buy
- Analyst Count
- HVT 0
- RIGL 5
- Target Price
- HVT N/A
- RIGL $38.20
- AVG Volume (30 Days)
- HVT 109.2K
- RIGL 768.1K
- Earning Date
- HVT 10-29-2025
- RIGL 11-06-2025
- Dividend Yield
- HVT 5.62%
- RIGL N/A
- EPS Growth
- HVT N/A
- RIGL N/A
- EPS
- HVT 1.17
- RIGL 5.43
- Revenue
- HVT $722,858,000.00
- RIGL $267,921,000.00
- Revenue This Year
- HVT $3.69
- RIGL $59.93
- Revenue Next Year
- HVT $8.33
- RIGL N/A
- P/E Ratio
- HVT $19.45
- RIGL $6.99
- Revenue Growth
- HVT N/A
- RIGL 105.62
- 52 Week Low
- HVT $17.01
- RIGL $12.76
- 52 Week High
- HVT $28.53
- RIGL $43.72
- Technical
- Relative Strength Index (RSI)
- HVT 50.12
- RIGL 56.17
- Support Level
- HVT $23.06
- RIGL $35.56
- Resistance Level
- HVT $24.00
- RIGL $42.65
- Average True Range (ATR)
- HVT 0.63
- RIGL 2.19
- MACD
- HVT -0.02
- RIGL -1.00
- Stochastic Oscillator
- HVT 29.46
- RIGL 32.70
About HVT Haverty Furniture Companies Inc.
Haverty Furniture Companies Inc is a specialty retailer of residential furniture and accessories. It provides various products such as Sofa Tables, Sleepers, End Tables, Cocktail Tables, Accent Pieces, Display Cabinets, Wall Decor, floral and Tress, and other related products. The company operates in the Southern and Midwestern U.S. All its activities are encompassed in its Merchandise division. The company derives the majority of its revenue from its upholstery products and, secondarily, from bedroom furniture.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.